Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
5Customers
2Debt Items
6Related Chains
Source-Backed Evidence Depth
Lisata Therapeutics, Inc. (LSTA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
4Distinct source URLs
8High confidence
0.792Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Lisata Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
QILU-PHARMACEUTICAL
QILU-PHARMACEUTICAL
90%
Study CEND1-201 was conducted in China by our former licensee, Qilu Pharmaceutical.
AUSTRALASIAN-GASTROINTESTINAL-CLINICAL-TRIALS-GR
AUSTRALASIAN-GASTROINTESTINAL-CLINICAL-TRIALS-GR
80%
We collaborated with the academic sponsor of the ASCEND trial, the Australasian Gastrointestinal Clinical Trials Group (AGITG) along with the University of Sydney to conduct the study.
CATALENT-INC
CATALENT-INC
80%
the Company granted to Catalent, on a non-exclusive basis, certain of
UNIVERSITY-OF-SYDNEY
UNIVERSITY-OF-SYDNEY
80%
We collaborated with the academic sponsor of the ASCEND trial, the Australasian Gastrointestinal Clinical Trials Group (AGITG) along with the University of Sydney to conduct the study.
Reciprocal relationship from MTNB graph: elopment, business management and knowledge of the pharmaceutical, health care and securities industries. Robin L. Smith, MD, MBA. Dr. Smith has served on the…
Lisata Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
KUVA-LABS-INC
KUVA-LABS-INC
92%
pursuant to which Kuva and Lisata agreed to negotiate in good faith and enter into a customary purchase agreement to consummate a negotiated acquisition of Lisata by Kuva
QILU-PHARMACEUTICAL-CO-LTD
QILU-PHARMACEUTICAL-CO-LTD
90%
the Company granted Qilu a royalty-bearing exclusive license for the research, development and commercialization of certepetide in the Greater China territory
CEND-THERAPEUTICS-INC
CEND-THERAPEUTICS-INC
62%
ns or warrants. Share-based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Co…
CO-LLC
CO-LLC
62%
a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of t…
WORKING-GROUP
WORKING-GROUP
62%
Cooperation Agreement between the European Union and the United Kingdom contains an Annex in relation to medicinal products with the objective of facilitating availability of medicines, promotion of …
Lisata Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
LSTA-DEBT-10808
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2010-12-31.
LSTA-DEBT-10807
Warrants outstanding: 10
90%
xbrl warrant detail from xbrl 2021-01-31.
Lisata Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Lisata Therapeutics, Inc..
Lisata Therapeutics, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Lisata Therapeutics, Inc..
Lisata Therapeutics, Inc. Extended Supply Chain Network
